Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors

Revolution Medicines, Inc. (RVMD), Summit Therapeutics PLC (SMMT) announced an update on their ongoing clinical study.

The Phase 1/2 study “A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors” tests new cancer drug mixes in people with advanced RAS‑mutated tumors. It aims to find safe doses and early signs of benefit, which could expand treatment options in lung and colorectal cancer.

The trial evaluates three oral RAS(ON) inhibitors – daraxonrasib, elironrasib, and zoldonrasib – each paired with ivonescimab, an IV antibody drug. Some study groups also add common chemo backbones or targeted drugs like carboplatin, cisplatin, pemetrexed, or cetuximab to see if combinations work better.

The study is interventional and non‑randomized, with patients assigned to fixed treatment arms instead of being randomized. It is open‑label, so doctors and patients know what they receive, and the main goal is to treat cancer while tracking safety, dose, and early tumor response.

The trial is listed as recruiting, with initial submission on February 2, 2026, signaling that sites are opening and enrollment is under way. The latest update on March 27, 2026, confirms the design and status, but key dates for primary and final completion are not yet posted, which is typical at this early stage.

For investors, this update strengthens the medium‑ to long‑term case for Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) by adding a broad, combination‑focused RAS program to their pipelines. With big players like Amgen and Mirati already active in RAS, any early efficacy hints here could boost sentiment and valuation, while setbacks may weigh on both stocks.

The study remains active and recruiting, with ongoing updates and full details available on the ClinicalTrials.gov portal under its registered identifier.

To learn more about RVMD’s potential, visit the Revolution Medicines, Inc. drug pipeline page.